cbdMD (YCBD) Non-Current Debt (2017 - 2024)
cbdMD (YCBD) posted Non-Current Debt of $1.0 million for Q3 2024, down 4.09% sequentially from $1.1 million in Q2 2024, and up 11476666.67% YoY from N/an in Q4 2023.
cbdMD (YCBD) Non-Current Debt (2017 - 2024) Analysis & Trends
cbdMD has reported Non-Current Debt for 8 years, with the latest figure at $1.0 million in Q3 2024.
- Quarterly Non-Current Debt rose 11476666.67% year-over-year to $1.0 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $1.0 million (up 11476666.67% YoY) and the FY2024 annual result came in at $1.0 million, up 11476666.67% from the prior year.
- Non-Current Debt fell to $1.0 million in Q3 2024 per YCBD's latest filing, from $1.1 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $1.5 million in Q1 2024 and troughed at $9.0 in Q3 2023.
- A 5-year average of $351158.8 and a median of $133582.0 in 2021 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2023 and 2024: Non-Current Debt tumbled 99.99% in 2023, then soared 11476666.67% in 2024.
- Over 5 years, Non-Current Debt stood at $516274.0 in 2020, then slumped by 81.89% to $93489.0 in 2021, then surged by 34.23% to $125491.0 in 2022, then sank by 99.99% to $9.0 in 2023, then jumped by 11476666.67% to $1.0 million in 2024.
- According to Business Quant data, Non-Current Debt over the past three periods registered $1.0 million, $1.1 million, and $1.5 million for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.45 Bn | 43.48 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.50 Bn | 39.84 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 32.42 Bn | 30.75 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.62 Bn | 22.82 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 21.99 Bn | 19.33 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.96 Bn | 18.08 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.03 Bn | 11.50 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 130.00 Mn |
| 10 | cbdMD | 5.39 Mn | 3.27 Mn | 3.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Sep 30, 2023 | 9.00 |
| Jun 30, 2023 | 819.00 |
| Sep 30, 2022 | 125,491.00 |
| Jun 30, 2022 | 127,949.00 |
| Mar 31, 2022 | 77,732.00 |
| Dec 31, 2021 | 93,489.00 |
| Sep 30, 2021 | 108,985.00 |
| Jun 30, 2021 | 124,226.00 |
| Mar 31, 2021 | 139,215.00 |
| Dec 31, 2020 | 516,274.00 |
| Sep 30, 2020 | 264,367.00 |
| Jun 30, 2020 | 182,714.00 |
| Mar 31, 2020 | 205,732.00 |
| Dec 31, 2019 | 182,975.00 |
| Mar 31, 2019 | 184,300.00 |
| Dec 31, 2018 | 184,300.00 |
| Mar 31, 2018 | 328,989.00 |